Evaluation of the effects of a proton pump inhibitor on Helicobacter pylori stool antigen testing
Helicobacter · 2023
DOI: 10.1111/hel.12961 ↗Kurz gefasst
Fachartikel in der Zeitschrift Helicobacter, 2023. Verfasst von Yusaku Kajihara und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Fuyoukai Murakami Hospital, Aomori, Japan. Hauptthemen laut MEDLINE: Helicobacter pylori, Helicobacter Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
Some patients find it difficult to discontinue proton pump inhibitors (PPIs). Unlike the 13 C‐urea breath test (UBT), the stool antigen test (SAT), particularly when domestically produced kits are used, may be less likely to yield false‐negative results.
Methods
This prospective study included a convenience series of 35 healthy Japanese subjects. Based on a statistical calculation, acceptable numbers of subjects were considered at least 21 and 11 with and without Helicobacter pylori ( H . pylori ) infection, respectively. The H . pylori infection was determined using the UBT or rapid urease test. SATs were performed with three novel domestically produced kits (the rapid immunochromatography tests Quick Navi™‐ H . pylori [Navi™] and Quick Chaser® H . pylori [Chaser®], and the bioluminescent enzyme immunoassay test BLEIA® ‘EIKEN’ H . pylori Antigen [BLEIA®]) before and after oral PPI administration (30 mg lansoprazole once daily for 14 days). For each kit, the sensitivities and specificities were calculated and compared before and after PPI administration. Furthermore, the cutoff index (COI) values of BLEIA® before and after PPI administration were compared in H . pylori ‐infected subjects.
Results
H . pylori infection was detected in 68.6% (24/35) of the included subjects. The sensitivities and specificities before versus after PPI administration were as follows: 79.2% (19/24) and 100.0% (11/11) versus 75.0% (18/24) and 100.0% (11/11) for Navi™, respectively ( p = 1); 87.5% (21/24) and 100.0% (11/11) versus 75.0% (18/24) and 100.0% (11/11) for Chaser®, respectively ( p = .371); 100.0% (24/24) and 100.0% (11/11) versus 95.8% (23/24) and 100.0% (11/11) for BLEIA®, respectively ( p = 1). The median COI values of BLEIA® before and after PPI administration were 1389.0 and 3207.25, respectively ( p = .0839).
Conclusions
In stool specimens, H . pylori antigenicity is maintained even during PPI use. SAT using a bioluminescent enzyme immunoassay is particularly recommended because of its extremely high sensitivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Fuyoukai Murakami Hospital, Aomori, Japan.
- Aomori General Health Examination Center, Aomori, Japan.
ORCID-Profile: Yusaku Kajihara, Tadashi Shimoyama
Zitieren
APA
Kajihara, Y., Shimoyama, T., & Mizuki, I. (2023). Evaluation of the effects of a proton pump inhibitor on Helicobacter pylori stool antigen testing. Helicobacter. https://doi.org/10.1111/hel.12961
Vancouver
Kajihara Y, Shimoyama T, Mizuki I. Evaluation of the effects of a proton pump inhibitor on Helicobacter pylori stool antigen testing. Helicobacter. 2023. doi:10.1111/hel.12961
BibTeX
@article{Kajihara2023,
author = {Kajihara, Yusaku and Shimoyama, Tadashi and Mizuki, Ichiro},
title = {Evaluation of the effects of a proton pump inhibitor on Helicobacter pylori stool antigen testing},
journal = {Helicobacter},
year = {2023},
doi = {10.1111/hel.12961}
}
EUVIMED